Cargando…
Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage
Intracerebral haemorrhage (ICH) has no specific treatment, but accounts for up to 15% of all strokes and has the highest mortality. Fingolimod (FTY720) is an immunomodulator approved for the management of multiple sclerosis, with abundant evidence of efficacy in experimental ischemic stroke, and mor...
Autores principales: | Diaz Diaz, Andrea C., Shearer, Jennifer A., Malone, Kyle, Waeber, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821021/ https://www.ncbi.nlm.nih.gov/pubmed/33488389 http://dx.doi.org/10.3389/fphar.2020.613103 |
Ejemplares similares
-
Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
por: Diaz Diaz, Andrea C., et al.
Publicado: (2022) -
The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia
por: Malone, Kyle, et al.
Publicado: (2021) -
Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE(−/−) mice in the presence and absence of immunomodulation with fingolimod
por: Diaz Diaz, Andrea C., et al.
Publicado: (2021) -
Long-term prognosis after intracerebral haemorrhage
por: van Nieuwenhuizen, Koen M, et al.
Publicado: (2020) -
Immunomodulatory Therapeutic Strategies in Stroke
por: Malone, Kyle, et al.
Publicado: (2019)